Toll Free: 1-888-928-9744

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2016

Published: Mar 22, 2016 | Pages: 91 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Chemotherapy Induced Peripheral Neuropathy - Pipeline Review, H1 2016', provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy
- The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects
- The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Chemotherapy Induced Peripheral Neuropathy Overview 9 Therapeutics Development 10 Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Overview 10 Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis 11 Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Development by Companies 12 Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 14 Chemotherapy Induced Peripheral Neuropathy - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Chemotherapy Induced Peripheral Neuropathy - Products under Development by Companies 17 Chemotherapy Induced Peripheral Neuropathy - Products under Investigation by Universities/Institutes 18 Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development 19 Achelios Therapeutics, Inc. 19 Amplyx Pharmaceuticals, Inc. 20 DermaXon, LLC 21 Eisai Co., Ltd. 22 Immune Pharmaceuticals Inc. 23 Kineta, Inc. 24 Laboratorios Del Dr. Esteve S.A. 25 MAKScientific, LLC 26 Mertiva AB 27 Midatech Pharma US Inc. 28 Nemus Bioscience, Inc. 29 Novartis AG 30 Panacea Pharmaceuticals, Inc. 31 PeriphaGen, Inc. 32 PharmatrophiX, Inc. 33 Spectrum Pharmaceuticals, Inc. 34 Virobay Inc. 35 Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment 36 Assessment by Monotherapy Products 36 Assessment by Combination Products 37 Assessment by Target 38 Assessment by Mechanism of Action 40 Assessment by Route of Administration 42 Assessment by Molecule Type 44 Drug Profiles 46 (amitriptyline + ketamine hydrochloride) - Drug Profile 46 Product Description 46 Mechanism of Action 46 R&D Progress 46 AM-1710 - Drug Profile 48 Product Description 48 Mechanism of Action 48 R&D Progress 48 AXPN-02 - Drug Profile 49 Product Description 49 Mechanism of Action 49 R&D Progress 49 BR-297 - Drug Profile 50 Product Description 50 Mechanism of Action 50 R&D Progress 50 DX-0332 - Drug Profile 51 Product Description 51 Mechanism of Action 51 R&D Progress 51 E-2072 - Drug Profile 52 Product Description 52 Mechanism of Action 52 R&D Progress 52 E-52862 - Drug Profile 53 Product Description 53 Mechanism of Action 53 R&D Progress 53 EMA-401 - Drug Profile 55 Product Description 55 Mechanism of Action 55 R&D Progress 55 Gene Therapy for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 57 Product Description 57 Mechanism of Action 57 R&D Progress 57 ketoprofen - Drug Profile 58 Product Description 58 Mechanism of Action 58 R&D Progress 58 KRN-5500 - Drug Profile 59 Product Description 59 Mechanism of Action 59 R&D Progress 59 LM11A-31BHS - Drug Profile 62 Product Description 62 Mechanism of Action 62 R&D Progress 62 NRX-2922 - Drug Profile 64 Product Description 64 Mechanism of Action 64 R&D Progress 64 PAN-811 - Drug Profile 65 Product Description 65 Mechanism of Action 65 R&D Progress 65 PGN-503 - Drug Profile 67 Product Description 67 Mechanism of Action 67 R&D Progress 67 Small Molecule for Pain - Drug Profile 68 Product Description 68 Mechanism of Action 68 R&D Progress 68 Small Molecules for Peripheral Neuropathy and Amyotrophic Lateral Sclerosis - Drug Profile 69 Product Description 69 Mechanism of Action 69 R&D Progress 69 Small Molecules to Agonize CB1 and CB2 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 70 Product Description 70 Mechanism of Action 70 R&D Progress 70 Small Molecules to Inhibit FKBP52 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 71 Product Description 71 Mechanism of Action 71 R&D Progress 71 SPI-205 - Drug Profile 72 Product Description 72 Mechanism of Action 72 R&D Progress 72 U-2902 - Drug Profile 73 Product Description 73 Mechanism of Action 73 R&D Progress 73 VBY-036 - Drug Profile 75 Product Description 75 Mechanism of Action 75 R&D Progress 75 Chemotherapy Induced Peripheral Neuropathy - Recent Pipeline Updates 77 Chemotherapy Induced Peripheral Neuropathy - Dormant Projects 84 Chemotherapy Induced Peripheral Neuropathy - Discontinued Products 85 Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones 86 Featured News & Press Releases 86 Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA 86 Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 86 Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA 87 Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation 88 Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development 88 Appendix 90 Methodology 90 Coverage 90 Secondary Research 90 Primary Research 90 Expert Panel Validation 90 Contact Us 90 Disclaimer 91
List of Tables
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2016 10 Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 13 Number of Products under Investigation by Universities/Institutes, H1 2016 14 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Development, H1 2016 16 Products under Development by Companies, H1 2016 17 Products under Investigation by Universities/Institutes, H1 2016 18 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Achelios Therapeutics, Inc., H1 2016 19 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Amplyx Pharmaceuticals, Inc., H1 2016 20 Chemotherapy Induced Peripheral Neuropathy - Pipeline by DermaXon, LLC, H1 2016 21 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Eisai Co., Ltd., H1 2016 22 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Immune Pharmaceuticals Inc., H1 2016 23 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Kineta, Inc., H1 2016 24 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Laboratorios Del Dr. Esteve S.A., H1 2016 25 Chemotherapy Induced Peripheral Neuropathy - Pipeline by MAKScientific, LLC, H1 2016 26 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Mertiva AB, H1 2016 27 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Midatech Pharma US Inc., H1 2016 28 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Nemus Bioscience, Inc., H1 2016 29 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Novartis AG, H1 2016 30 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Panacea Pharmaceuticals, Inc., H1 2016 31 Chemotherapy Induced Peripheral Neuropathy - Pipeline by PeriphaGen, Inc., H1 2016 32 Chemotherapy Induced Peripheral Neuropathy - Pipeline by PharmatrophiX, Inc., H1 2016 33 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Spectrum Pharmaceuticals, Inc., H1 2016 34 Chemotherapy Induced Peripheral Neuropathy - Pipeline by Virobay Inc., H1 2016 35 Assessment by Monotherapy Products, H1 2016 36 Assessment by Combination Products, H1 2016 37 Number of Products by Stage and Target, H1 2016 39 Number of Products by Stage and Mechanism of Action, H1 2016 41 Number of Products by Stage and Route of Administration, H1 2016 43 Number of Products by Stage and Molecule Type, H1 2016 45 Chemotherapy Induced Peripheral Neuropathy Therapeutics - Recent Pipeline Updates, H1 2016 77 Chemotherapy Induced Peripheral Neuropathy - Dormant Projects, H1 2016 84 Chemotherapy Induced Peripheral Neuropathy - Discontinued Products, H1 2016 85


List of Figures
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H1 2016 10 Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis, H1 2016 11 Number of Products under Development by Companies, H1 2016 12 Comparative Analysis by Clinical Stage Development, H1 2016 15 Comparative Analysis by Early Stage Products, H1 2016 16 Assessment by Monotherapy Products, H1 2016 36 Number of Products by Top 10 Targets, H1 2016 38 Number of Products by Stage and Top 10 Targets, H1 2016 38 Number of Products by Top 10 Mechanism of Actions, H1 2016 40 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 40 Number of Products by Routes of Administration, H1 2016 42 Number of Products by Stage and Routes of Administration, H1 2016 42 Number of Products by Molecule Types, H1 2016 44 Number of Products by Stage and Molecule Types, H1 2016 44

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global microcontroller market is estimated to be valued at USD 26.9 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing demand in key application areas such as automotive, consumer electronics and healthcare is expected to

Read More...

Global aerospace plastics market size is likely to be valued at USD 13.48 billion by 2020; as per a new research report by Radiant Insights, Inc. Growing application scope of lightweight materials in aerospace industry is likely to drive market growt

Read More...

Global automotive relay market is anticipated to reach USD 12 billion by 2020, as per a new research report by Radiant Insights, Inc. Rising need for high-frequency signals in automotive industry is expected to drive demand. These relays enhance driv

Read More...

Global electric water heaters market is expected to be valued at USD 29,322.4 million by 2022, as per a new research report by Radiant Insights, Inc. Escalating demand across extensive range of domestic applications is expected to drive demand. Evolv

Read More...

Global non destructive testing equipment market is anticipated to reach USD 5.76 billion by 2022, as per a new research report by Radiant Insights, Inc. Stringent government safety initiatives for inspection and quality control across numerous indust

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify